BRISTOL MYERS SQUIBB CO
For the period ended Mar 31, 2024. Filed Apr 25, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed Apr 25, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Summary of Abbreviated Terms
Bristol-Myers Squibb Company and its consolidated subsidiaries may be referred to as Bristol Myers Squibb, BMS, the Company, we, our or us in this Quarterly Report on Form 10-Q, unless the context otherwise indicates. Throughout this Quarterly Report on Form 10-Q we have used terms which are defined below:
| 2023 Form 10-K | Annual Report on Form 10-K for the fiscal year ended December 31, 2023 | Mirati | Mirati Therapeutics, Inc. |
|---|---|---|---|
| 2024 Senior Unsecured Notes | Aggregate principal amount of $13.0 billion of unsecured senior notes issued by BMS in February 2024 | MPM | malignant pleural mesothelioma |
| aGVHD | acute graft-versus-host disease | NKT | natural killer T cells |
| ANDA | Abbreviated New Drug Application | NDA | New Drug Application |
| AstraZeneca | AstraZeneca PLC | NSCLC | non-small cell lung cancer |
| BCMA | B-cell maturation antigen-directed | Nimbus | Nimbus Therapeutics |
| CAR-T | chimeric antigen receptor T-cell | NVAF | non-valvular atrial fibrillation |
| Celgene | Celgene Corporation | OECD | Organization for Economic Co-operation and Development |
| CERCLA | U.S. Comprehensive Environmental Response, Compensation and Liability Act | Ono | Ono Pharmaceutical Co., Ltd |
| CGDP | Coverage Gap Discount Program | Otsuka | Otsuka Pharmaceutical Co., Ltd. |
| CML | chronic myeloid leukemia | PD-1 | programmed cell death protein 1 |
| CRC | colorectal carcinoma | PD-L1 | programmed death-ligand 1 |
| EC | European Commission | PDUFA | Prescription Drug User Fee Act |
| EPS | earnings per share | PsA | psoriatic arthritis |
| ESA | erythropoiesis stimulating agent | Quarterly Report on Form 10-Q | Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 |
| EU | European Union | R&D | research and development |
| Exchange Act | the Securities Exchange Act of 1934 | RA | rheumatoid arthritis |
| FDA | U.S. Food and Drug Administration | RayzeBio | RayzeBio, Inc. |
| FL | follicular lymphoma | RCC | renal cell carcinoma |
| GAAP | generally accepted accounting principles | REMS | risk evaluation and mitigation strategy |
| GTN | gross-to-net | Sanofi | Sanofi S.A. |
| HCC | hepatocellular carcinoma | SEC | U.S. Securities and Exchange Commission |
| HCM | hypertrophic cardiomyopathy | Section 174 | Guidance on amortization of specified research or experimental expenditures under Section 174 Notice 2023-63 |
| IMDC | International Metastatic - Renal Cell Carcinoma Database Consortium | sNDA | Supplemental New Drug Application |
| IPRD | in-process research and development | SPC | Supplementary Protection Certificate |
| IRA | Inflation Reduction Act of 2022 | SystImmune | SystImmune, Inc. |
| IRS | Internal Revenue Service | Takeda | Takeda Pharmaceutical Company Limited |
| IV | intravenous | Turning Point | Turning Point Therapeutics, Inc. |
| JIA | juvenile idiopathic arthritis | UC | ulcerative colitis |
| Juno | Juno Therapeutics, Inc. | UK | United Kingdom |
| Karuna | Karuna Therapeutics, Inc. | U.S. | United States |
| MDL | multi-district litigation | USPTO | U.S. Patent and Trademark Office |
| MDS | myelodysplastic syndromes | VAT | value added tax |
| Merck | Merck & Co. | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.